Kalydeco (ivacaftor)

pCPA File Number: 21250

Negotiation Status:

Concluded with an LOI

Indication(s):

Cystic Fibrosis In Patients with CFTR Gating Mutations or the R117H Gating Mutation

Sponsor/Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-06-12

Negotiation Process Concluded:

2021-06-03